Mifepristone Prescribing After Dobbs: Legal and Ethical Risks
This paper examines the legal and ethical implications of prescribing mifepristone in the post-Roe regulatory environment, with particular focus on North Carolina's restrictive abortion laws. Following the Supreme Court's 2022 decision in Dobbs v. Jackson Women's Health Organization, which overturned Roe v. Wade and Planned Parenthood v. Casey, individual states regained authority over abortion regulation. The paper explores the tension between the FDA's expanded telemedicine access to mifepristone and North Carolina's restrictive state statutes, assesses institutional legal exposure, draws a partial analogy to assisted-suicide drug use, and ultimately recommends that affiliated healthcare providers refrain from prescribing mifepristone for abortion induction until the legal landscape clarifies.
- Introduction: The Post-Roe Regulatory Shift: Dobbs overturns Roe, states regain abortion authority
- North Carolina Abortion Law and Mifepristone: NC restricts abortion; mifepristone law unclear
- FDA Policy and Telemedicine Access: FDA expands mifepristone via telemedicine despite state laws
- Institutional Legal and Ethical Exposure: Prescribing mifepristone risks legal and reputational harm
- Analogy to Assisted Suicide Drug Use: Assisted suicide comparison highlights key legal distinctions
- Recommendations and Conclusion: Recommends withholding mifepristone prescriptions for now
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- It moves systematically from legal context to institutional risk to a concrete recommendation, giving the argument a clear and logical progression.
- The assisted-suicide analogy demonstrates analytical nuance — the paper introduces the comparison and then critically limits it, acknowledging where it breaks down rather than overstating its explanatory power.
- Concise use of current citations (2020–2023) grounds policy claims in recent scholarship, appropriate for a professional or graduate-level memo format.
Key academic technique demonstrated
The paper demonstrates applied ethical and legal reasoning: it identifies a gap between federal regulatory action (FDA telemedicine expansion) and state law (North Carolina abortion restrictions), then uses that tension to assess institutional risk and produce a defensible policy recommendation. This technique — identifying jurisdictional conflict and reasoning to a practical conclusion — is characteristic of health law and bioethics writing.
Structure breakdown
The paper opens with the Dobbs decision as the triggering event, then narrows successively: from state law, to FDA policy, to institutional exposure, to an analogical comparison, and finally to a recommendation. Each section is short and focused, resembling a professional policy memo more than a traditional academic essay, which suits its evident audience of institutional decision-makers.
Introduction: The Post-Roe Regulatory Shift
In June 2022, the Supreme Court overturned Roe v. Wade and Planned Parenthood v. Casey, effectively returning the authority to regulate abortion to individual states. This decision has brought significant changes to state laws and has directly impacted the use of mifepristone, a drug used to medically induce abortions.
North Carolina Abortion Law and Mifepristone
In North Carolina, post-Roe abortion laws are stringent, permitting abortion only in specific circumstances (Reamer, 2023). Currently, the state does not have explicit legislation concerning the use of mifepristone. However, considering the state's restrictive stance on abortion, the use of mifepristone outside of these narrowly defined circumstances could be viewed as illegal.
FDA Policy and Telemedicine Access
Despite state restrictions, the FDA, under executive direction, has expanded mifepristone's availability via telemedicine appointments, with the drug shipped directly to patients (Baker, 2023). This unprecedented move challenges the authority of state abortion laws, including those of North Carolina.
References
Baker, C. N. (2023). History and politics of medication abortion in the United States and the rise of telemedicine and self-managed abortion. Journal of Health Politics, Policy and Law, 10449941.
de Vries, I., van Keizerswaard, L. J., Tolboom, B., Bulthuis, S., van der Kwaak, A., Tank, J., & de Koning, K. (2020). Advocating safe abortion: Outcomes of a multi-country needs assessment on the potential role of national societies of obstetrics and gynecology. International Journal of Gynecology & Obstetrics, 148(3), 282–289.
Reamer, F. G. (2023). Ethical practice in a post-Roe world: A guide for social workers. Social Work, 68(2), 150–158.
Redd, S. K., AbiSamra, R., Blake, S. C., Komro, K. A., Neal, R., Rice, W. S., & Hall, K. S. (2023). Medication abortion "reversal" laws: How unsound science paved the way for dangerous abortion policy. American Journal of Public Health, 113(2), 202–212.
Saxe, L. (2022). No longer viable: The push for the FDA's removal of mifepristone from the REMS program under Dobbs. Admin. L. Rev. Accord, 8, 101.
Always verify citation format against your institution’s current style guide requirements.